Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 9.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,766 shares of the company’s stock after buying an additional 4,518 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.19% of Dianthus Therapeutics worth $1,194,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in DNTH. TCG Crossover Management LLC acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth $32,735,000. Braidwell LP increased its holdings in shares of Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after buying an additional 712,902 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Dianthus Therapeutics during the 4th quarter worth $3,924,000. Alliancebernstein L.P. boosted its position in Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after purchasing an additional 136,633 shares during the period. Finally, Ally Bridge Group NY LLC purchased a new stake in Dianthus Therapeutics during the 4th quarter worth $2,320,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday. Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $53.00.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $18.84 on Wednesday. The firm has a 50-day moving average of $19.68 and a two-hundred day moving average of $22.30. The stock has a market cap of $605.25 million, a P/E ratio of -7.54 and a beta of 1.48. Dianthus Therapeutics, Inc. has a 1-year low of $13.37 and a 1-year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.